Evolus raises FY2023 revenue guidance to $185-195M, Q2 revenue $49.3M (+33% YoY)

Evolus, Inc.

2023-Q2 EPS reported -$0.58 revenue$91,067,000

Q2 net revenue $49.3M, up 33% YoY, a new quarterly record.
FY2023 revenue guidance raised to $185-195M from prior $180-190M.
Record ~800 new accounts, 64k new patient enrollments, 147k+ redemptions.
Expanding into fillers in 2025; targeting $700M revenue by 2028.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evolus, Inc. reported the second quarter ended June 30, 2023 results: revenue $49.3 million. Guidance raised.

Period: the second quarter ended June 30, 2023
Revenue: $49.3 million
Guidance: raised
Result: reported results

Exact text from the filing

Guidance on Record Second Quarter 2023 Revenue • Company Increases Full-Year 2023 Net Revenue Guidance to $185 to $195 Million • Company Achieved Quarterly Net Revenue of $49.3 Million, Growing 33% Year-over-Year and 10 Percentage Points Above the First Quarter’s Growth Rate • Achieved Record Growth and All-time Highs in New Accounts and Consumer Loyalty

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

Evolus, Inc. filing history →

Source: SEC EDGAR

accession 0001570562-23-000082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.